207 related articles for article (PubMed ID: 22827519)
21. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
22. Structural basis for the design and synthesis of selective HDAC inhibitors.
Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
[TBL] [Abstract][Full Text] [Related]
23. Current status in the discovery of dual BET/HDAC inhibitors.
Ren Q; Gao W
Bioorg Med Chem Lett; 2021 Jan; 31():127671. PubMed ID: 33229136
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, biological characterization and molecular modeling insights of spirochromanes as potent HDAC inhibitors.
Thaler F; Moretti L; Amici R; Abate A; Colombo A; Carenzi G; Fulco MC; Boggio R; Dondio G; Gagliardi S; Minucci S; Sartori L; Varasi M; Mercurio C
Eur J Med Chem; 2016 Jan; 108():53-67. PubMed ID: 26629860
[TBL] [Abstract][Full Text] [Related]
25. Isoform-selective histone deacetylase inhibitors.
Itoh Y; Suzuki T; Miyata N
Curr Pharm Des; 2008; 14(6):529-44. PubMed ID: 18336298
[TBL] [Abstract][Full Text] [Related]
26. Azetidinones as zinc-binding groups to design selective HDAC8 inhibitors.
Galletti P; Quintavalla A; Ventrici C; Giannini G; Cabri W; Penco S; Gallo G; Vincenti S; Giacomini D
ChemMedChem; 2009 Dec; 4(12):1991-2001. PubMed ID: 19821480
[TBL] [Abstract][Full Text] [Related]
27. Cell-based multi-substrate assay coupled to UHPLC-ESI-MS/MS for a quick identification of class-specific HDAC inhibitors.
Zwick V; Simões-Pires C; Cuendet M
J Enzyme Inhib Med Chem; 2016; 31(sup1):209-214. PubMed ID: 27149362
[TBL] [Abstract][Full Text] [Related]
28. Selective Histone Deacetylase Inhibitors with Anticancer Activity.
Ma N; Luo Y; Wang Y; Liao C; Ye WC; Jiang S
Curr Top Med Chem; 2016; 16(4):415-26. PubMed ID: 26268343
[TBL] [Abstract][Full Text] [Related]
29. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
Cai J; Wei H; Hong KH; Wu X; Cao M; Zong X; Li L; Sun C; Chen J; Ji M
Eur J Med Chem; 2015; 96():1-13. PubMed ID: 25874326
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of nigranoic acid and manwuweizic acid derivatives as HDAC inhibitors and anti-inflammatory agents.
Ni DX; Wang Q; Li YM; Cui YM; Shen TZ; Li XL; Sun HD; Zhang XJ; Zhang R; Xiao WL
Bioorg Chem; 2021 Apr; 109():104728. PubMed ID: 33636436
[TBL] [Abstract][Full Text] [Related]
31. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.
Seidel C; Schnekenburger M; Zwergel C; Gaascht F; Mai A; Dicato M; Kirsch G; Valente S; Diederich M
Bioorg Med Chem Lett; 2014 Aug; 24(16):3797-801. PubMed ID: 25042254
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
Reddy DR; Ballante F; Zhou NJ; Marshall GR
Eur J Med Chem; 2017 Feb; 127():531-553. PubMed ID: 28109947
[TBL] [Abstract][Full Text] [Related]
33. Development of an ELISA-Based HDAC Activity Assay for Characterization of Isoform-Selective Inhibitors.
Padige G; Negmeldin AT; Pflum MK
J Biomol Screen; 2015 Dec; 20(10):1277-85. PubMed ID: 26232305
[TBL] [Abstract][Full Text] [Related]
34. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
Zhang X; Zhang J; Tong L; Luo Y; Su M; Zang Y; Li J; Lu W; Chen Y
Bioorg Med Chem; 2013 Jun; 21(11):3240-4. PubMed ID: 23602523
[TBL] [Abstract][Full Text] [Related]
35. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
36. A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.
Kemp MM; Wang Q; Fuller JH; West N; Martinez NM; Morse EM; Weïwer M; Schreiber SL; Bradner JE; Koehler AN
Bioorg Med Chem Lett; 2011 Jul; 21(14):4164-9. PubMed ID: 21696956
[TBL] [Abstract][Full Text] [Related]
37. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.
Lobera M; Madauss KP; Pohlhaus DT; Wright QG; Trocha M; Schmidt DR; Baloglu E; Trump RP; Head MS; Hofmann GA; Murray-Thompson M; Schwartz B; Chakravorty S; Wu Z; Mander PK; Kruidenier L; Reid RA; Burkhart W; Turunen BJ; Rong JX; Wagner C; Moyer MB; Wells C; Hong X; Moore JT; Williams JD; Soler D; Ghosh S; Nolan MA
Nat Chem Biol; 2013 May; 9(5):319-25. PubMed ID: 23524983
[TBL] [Abstract][Full Text] [Related]
38. An efficient synthesis of SK-658 and its analogs as potent histone deacetylase inhibitors.
Shahidul Islam M; Nurul Islam M; Ashraful Hoque M; Nishino N; Kato T; Kim HJ; Ito A; Yoshida M
Bioorg Chem; 2015 Apr; 59():145-50. PubMed ID: 25797804
[TBL] [Abstract][Full Text] [Related]
39. A series of camptothecin prodrugs exhibit HDAC inhibition activity.
Zhu Q; Yu X; Shen Q; Zhang Q; Su M; Zhou Y; Li J; Chen Y; Lu W
Bioorg Med Chem; 2018 Sep; 26(16):4706-4715. PubMed ID: 30115492
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of novel isoxazole-based HDAC inhibitors.
Conti P; Tamborini L; Pinto A; Sola L; Ettari R; Mercurio C; De Micheli C
Eur J Med Chem; 2010 Sep; 45(9):4331-8. PubMed ID: 20637529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
